Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIRSEVIMAB-ALIP Cause Drug ineffective? 173 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 173 reports of Drug ineffective have been filed in association with NIRSEVIMAB-ALIP. This represents 22.1% of all adverse event reports for NIRSEVIMAB-ALIP.

173
Reports of Drug ineffective with NIRSEVIMAB-ALIP
22.1%
of all NIRSEVIMAB-ALIP reports
1
Deaths
127
Hospitalizations

How Dangerous Is Drug ineffective From NIRSEVIMAB-ALIP?

Of the 173 reports, 1 (0.6%) resulted in death, 127 (73.4%) required hospitalization, and 19 (11.0%) were considered life-threatening.

Is Drug ineffective Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIRSEVIMAB-ALIP. However, 173 reports have been filed with the FAERS database.

What Other Side Effects Does NIRSEVIMAB-ALIP Cause?

Respiratory syncytial virus bronchiolitis (135) Bronchiolitis (83) Incorrect dose administered (80) Respiratory syncytial virus infection (76) Pyrexia (54) Cough (45) Respiratory syncytial virus test positive (36) Extra dose administered (30) Product storage error (30) Rash (25)

What Other Drugs Cause Drug ineffective?

ADALIMUMAB (71,926) METHOTREXATE (70,142) ETANERCEPT (60,367) ADAPALENE (52,181) ABATACEPT (35,212) INFLIXIMAB (33,738) TOCILIZUMAB (32,342) RITUXIMAB (32,186) LEFLUNOMIDE (31,396) HYDROXYCHLOROQUINE (31,057)

Which NIRSEVIMAB-ALIP Alternatives Have Lower Drug ineffective Risk?

NIRSEVIMAB-ALIP vs NITAZOXANIDE NIRSEVIMAB-ALIP vs NITISINONE NIRSEVIMAB-ALIP vs NITRAZEPAM NIRSEVIMAB-ALIP vs NITRENDIPINE NIRSEVIMAB-ALIP vs NITRIC

Related Pages

NIRSEVIMAB-ALIP Full Profile All Drug ineffective Reports All Drugs Causing Drug ineffective NIRSEVIMAB-ALIP Demographics